journal article·2024-08Open access

An iron-containing nanomedicine for inducing deep tumor penetration and synergistic ferroptosis in enhanced pancreatic cancer therapy

Aiping Huang, Qingnian Li, Xinyi Shi, Junyi Gao, Yiran Ma, Jinsong Ding, Surong Hua, Wenhu Zhou

Abstract

Pancreatic cancer is an aggressive and challenging malignancy with limited treatment options, largely attributed to the dense tumor stroma and intrinsic drug resistance. Here, we introduce a novel iron-containing nanoparticle formulation termed PTFE, loaded with the ferroptosis inducer Erastin, to overcome these obstacles and enhance pancreatic cancer therapy. The PTFE nanoparticles were prepared through a one-step assembly process, consisting of an Erastin-loaded PLGA core stabilized by a MOF shell formed by coordination between Fe 3+ and tannic acid. PTFE demonstrated a unique capability to repolarize tumor-associated macrophages (TAMs) into the M1 phenotype, leading to the regulation of dense tumor stroma by modulating the activation of tumor-associated fibroblasts (TAFs) and reducing collagen deposition. This resulted in enhanced nanoparticle accumulation and deep penetration, as confirmed by in vitro multicellular tumor spheroids and in vivo mesenchymal-rich subcutaneous pancreatic tumor models. Moreover, PTFE effectively combated tumor resistance by synergistically employing the Fe 3+ -induced Fenton reaction and Erastin-induced ferroptosis, thereby disrupting the redox balance. As a result, significant tumor growth inhibition was achieved in mice-bearing tumor model. Comprehensive safety evaluations demonstrated PTFE's favorable biocompatibility, highlighting its potential as a promising therapeutic platform to effectively address the formidable challenges in pancreatic cancer treatment. This study presents a deep tumour penetration and synergistic iron metabolic response drug delivery system. Through the synergistic effect of iron ions and Erastin, PTFE regulated TAFs and tumor dense stroma by inducing M2-to-M1 polarization of macrophages, thereby improving nanoparticle permeability and overcoming drug delivery barriers. Meanwhile, the formulation disrupts the redox balance at the tumor site, inducing ferroptosis in cancer cells, and presents a promising therapeutic strategy for pancreatic cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Extracellular vesicles in disease · Pancreatic and Hepatic Oncology Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Pancreatic cancer10.1001/jama.2019.14699 ↗
2. Pancreatic cancer: advances and challenges10.1016/j.cell.2023.02.014 ↗
3. Bio-assembled smart nanocapsules for targeted delivery of KRAS shRNA and cancer cell bioimage10.1016/j.cclet.2022.06.074 ↗
4. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors10.1016/j.jconrel.2023.03.016 ↗
5. Transforming growth factor-β blockade in pancreatic cancer enhances sensitivity to combination chemotherapy10.1053/j.gastro.2023.05.038 ↗
6. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion10.1016/j.ccell.2021.08.008 ↗
7. Macrophage-targeted nanomedicine for chronic diseases immunotherapy10.1016/j.cclet.2021.08.090 ↗
8. Pancreatic cancer stroma: an update on therapeutic targeting strategies10.1038/s41575-020-0300-1 ↗
9. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment10.1016/j.biomaterials.2020.119999 ↗
10. Transcytosis mediated deep tumor penetration for enhanced chemotherapy and immune activation of pancreatic cancer10.1002/adfm.202214937 ↗
11. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
12. A synergistic optical strategy for enhanced deep-tumor penetration and therapy in the second near-infrared window10.1039/D0MH00870B ↗
13. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system10.1016/j.jconrel.2016.09.014 ↗
14. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer10.1158/1535-7163.MCT-10-0172 ↗
15. Tailored chemodynamic nanomedicine improves pancreatic cancer treatment via controllable damaging neoplastic cells and reprogramming tumor microenvironment10.1021/acs.nanolett.0c02622 ↗
16. Tumor-associated fibroblast-targeted regulation and deep tumor delivery of chemotherapeutic drugs with a multifunctional size-switchable nanoparticle10.1021/acsami.9b13957 ↗
17. Redox dyshomeostasis with dual stimuli-activatable dihydroartemisinin nanoparticles to potentiate ferroptotic therapy of pancreatic cancer10.1002/smtd.202200888 ↗
18. A self-assembly combined nano-prodrug to overcome gemcitabine chemo-resistance of pancreatic tumors10.1002/adfm.202214598 ↗
19. Targeting ferroptosis in pancreatic cancer: a double-edged sword10.1016/j.trecan.2021.04.005 ↗
20. Iron(III)–siderophore coordination chemistry: reactivity of marine siderophores10.1016/j.ccr.2009.09.010 ↗
21. Regulation of ferroptotic cancer cell death by GPX410.1016/j.cell.2013.12.010 ↗
22. Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression10.1016/j.redox.2023.102822 ↗
23. How erastin assassinates cells by ferroptosis revealed
24. Cysteine depletion induces pancreatic tumor ferroptosis in mice10.1126/science.aaw9872 ↗
25. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth10.1038/nm.4232 ↗
26. Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme10.1016/j.nantod.2022.101722 ↗
27. Anti-PD-L1 DNAzyme loaded photothermal Mn2+/Fe3+ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosis-immunotherapy
28. Radicals scavenging MOFs enabling targeting delivery of siRNA for rheumatoid arthritis therapy10.1002/smll.202202604 ↗
29. Core–shell nanosystems for self-activated drug–gene combinations against triple-negative breast cancer10.1021/acsami.0c15089 ↗
30. Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy10.1016/j.jconrel.2020.10.069 ↗
31. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment10.1016/j.cclet.2022.05.032 ↗
32. A recombinant Newcastle disease virus expressing MMP8 promotes oncolytic efficacy10.1016/j.cclet.2021.05.001 ↗
33. Modulating tumor extracellular matrix by simultaneous inhibition of two cancer cell receptors10.1002/adma.202109376 ↗
34. Applications of surface modification technologies in nanomedicine for deep tumor penetration10.1002/advs.202002589 ↗
35. Effect of macrophages on pancreatic cancer10.1200/JCO.2018.36.4_suppl.324 ↗
36. Biodegradable nanoparticles inhibit tumor growth by altering tumor-associated macrophages and cancer-associated fibroblasts10.1200/JCO.2022.40.16_suppl.e14553 ↗
37. The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC)10.1200/JCO.2022.40.16_suppl.4142 ↗
38. Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway10.1016/j.apsb.2021.03.009 ↗
39. Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer10.1016/j.canlet.2022.216021 ↗
40. Mechanism of iron oxide-induced macrophage activation: the impact of composition and the underlying signaling pathway10.1021/jacs.8b10904 ↗
41. Boosting ferroptosis and microtubule inhibition for antitumor therapy via a carrier-free supermolecule nanoreactor10.1016/j.jpha.2022.09.003 ↗
42. Iron administration overcomes resistance to erastin-mediated ferroptosis in ovarian cancer cells10.3389/fonc.2022.868351 ↗
43. Arginine expedites erastin-induced ferroptosis through fumarate [J/OL]